Aspirin protects low density lipoprotein from oxidative modification

K A Steer, T M Wallace, C H Bolton, M Hartog, K A Steer, T M Wallace, C H Bolton, M Hartog

Abstract

Objective: To examine the effects of aspirin on the potential for oxidative modification of low density lipoprotein (LDL).

Design: Before and after trial.

Setting: University department of medicine within a district general hospital campus.

Patients: Ten healthy normolipidaemic volunteers drawn from laboratory and medical staff.

Interventions: Aspirin (enteric coated) 300 mg daily for two weeks.

Main outcome measures: In vitro oxidation of LDL following ultraviolet C (UVC) irradiation with measurements made of malondialdehyde, conjugated dienes, and electrophoretic mobility.

Results: There was a significant decrease in malondialdehyde production from LDL modified by aspirin in vivo following exposure to UVC irradiation for 90 minutes, culminating in a 30% decrease by 240 minutes (mean (SD) 64.2 (9.12) v 89.6 (11.6) nmol/mg LDL protein, P = 0.029). These observations were borne out using LDL modified by aspirin in vitro. The UVC induced increase in relative electrophoretic mobility of LDL was also significantly reduced following aspirin treatment (mean (SD) 2.17 (0.16) v 2.66 (0.24), P = 0.012).

Conclusions: Aspirin, both in vivo and in vitro, protects LDL against subsequent oxidative modification, providing an additional mechanism whereby aspirin may protect against atherosclerosis.

References

    1. Circ Res. 1986 Dec;59(6):612-9
    1. Biochem J. 1986 Jul 15;237(2):499-504
    1. FEBS Lett. 1987 Jun 29;218(2):243-6
    1. Chem Phys Lipids. 1987 Nov-Dec;45(2-4):315-36
    1. Dig Dis Sci. 1987 Dec;32(12):1395-401
    1. J Clin Invest. 1988 Jan;81(1):165-70
    1. N Engl J Med. 1989 Apr 6;320(14):915-24
    1. Proc Natl Acad Sci U S A. 1990 May;87(10):3894-8
    1. Chem Res Toxicol. 1990 Mar-Apr;3(2):77-92
    1. Ann Clin Biochem. 1991 Sep;28 ( Pt 5):504-8
    1. J Chromatogr. 1991 Dec 6;572(1-2):103-16
    1. Clin Chem. 1992 Oct;38(10):2066-72
    1. Biochem Mol Biol Int. 1993 Apr;29(5):921-8
    1. Biochim Biophys Acta. 1993 Oct 3;1158(2):107-12
    1. Comp Biochem Physiol Pharmacol Toxicol Endocrinol. 1994 Jul;108(2):145-52
    1. N Engl J Med. 1995 Nov 16;333(20):1301-7
    1. Am J Med. 1956 Jul;21(1):34-46
    1. Nature. 1968 Jul 6;219(5149):68-9
    1. J Clin Invest. 1969 Mar;48(3):536-42
    1. Proc Natl Acad Sci U S A. 1973 Dec;70(12):3707-10
    1. Proc Natl Acad Sci U S A. 1976 Sep;73(9):3178-82
    1. Proc Natl Acad Sci U S A. 1979 Jan;76(1):333-7
    1. Atherosclerosis. 1979 Mar;32(3):213-29
    1. J Clin Invest. 1979 Sep;64(3):743-50
    1. Proc Natl Acad Sci U S A. 1980 Apr;77(4):2214-8
    1. Proc Natl Acad Sci U S A. 1981 Oct;78(10):6499-503
    1. Annu Rev Biochem. 1983;52:223-61
    1. Ann Clin Biochem. 1985 Mar;22 ( Pt 2):137-40
    1. Proc Natl Acad Sci U S A. 1985 Sep;82(17):5949-53
    1. Proc Natl Acad Sci U S A. 1987 May;84(9):2995-8

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe